Evaluation of the Immunogenicity of a Potyvirus-Like Particle as an Adjuvant of a Synthetic Peptide.
Improvement of current vaccines is highly necessary to increase immunogenicity levels and protection against several pathogens. Virus-like particles (VLPs) are promising approaches for vaccines because they emulate infectious virus structure, but lack any genetic material needed for replication. Plant viruses have emerged as a potential framework for VLP design, mainly because there is no preexisting immunity in mammals. In this study, we evaluated the scaffold of the papaya ringspot virus (PRSV) as a VLP adjuvant for a short synthetic peptide derived from the Hemagglutinin protein of AH1 N1 influenza virus-hemagglutinin (VLP-HA). Our results demonstrated that the adjuvant property of this VLP is highly similar to the trivalent influenza vaccine, showing comparable levels of IgG- and IgA-specific antibodies to HA-derived peptide in serum and feces of vaccinated mice, respectively. Furthermore, VLP-HA-immunized mice showed Th1-biased immune response as suggested by measuring IgG subclasses in comparison with the predominance of Th2-biased immune response in trivalent influenza vaccine dose-vaccinated mice. VLP-HA administration in mice induced comparable levels of activated CD4+- and CD8+-specific T lymphocytes for the HA-derived peptide. These results suggest the potential adjuvant capacity of the PRSV-VLP as a carrier for short synthetic peptides.
1 Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco , Guadalajara, México .|2 Departamento de Fisiología, Centro Universitario de Ciencias de la Salud , Guadalajara, México .
Albertina
A
Cárdenas-Vargas
1 Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco , Guadalajara, México .
Darwin
D
Elizondo-Quiroga
1 Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco , Guadalajara, México .
Abel
A
Gutierrez-Ortega
3 Departamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara , Guadalajara, México .
Claudia
C
Charles-Niño
4 Departamento de Medicina Veterinaria, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara , Zapopan, México .
César
C
Pedroza-Roldán
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D036022:Capsid Proteins / Q000276:immunology*; D004337:Drug Carriers / Q000008:administration & dosage; D005260:Female; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000008:administration & dosage / Q000276:immunology*; D000071497:Immunogenicity, Vaccine; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007279:Injections, Subcutaneous; D051379:Mice; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology; D017800:Potyvirus / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D013047:Specific Pathogen-Free Organisms; D058425:Vaccines, Virus-Like Particle / Q000276:immunology*
D000276:Adjuvants, Immunologic; D036022:Capsid Proteins; D004337:Drug Carriers; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D010455:Peptides; D011994:Recombinant Proteins; D058425:Vaccines, Virus-Like Particle; C073700:coat protein, Papaya ringspot virus
adjuvant; immunogenicity; papaya ringspot virus